Analysts’ Weekly Ratings Changes for Exact Sciences (EXAS)

A number of research firms have changed their ratings and price targets for Exact Sciences (NASDAQ: EXAS):

• 1/30/2026 – Exact Sciences was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 1/22/2026 – Exact Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – Exact Sciences had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $105.00 price target on the stock, up previously from $85.00.
• 1/20/2026 – Exact Sciences was downgraded by analysts at Mizuho from an “outperform” rating to a “neutral” rating. They now have a $105.00 price target on the stock, up previously from $85.00.
• 1/5/2026 – Exact Sciences was given a new $105.00 price target on by analysts at Evercore Inc. They now have an “in-line” rating on the stock.
• 1/1/2026 – Exact Sciences was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.

Insider Activity

In other news, EVP Jacob A. Orville sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $75.00, for a total transaction of $375,000.00. Following the sale, the executive vice president owned 23,237 shares of the company’s stock, valued at $1,742,775. This trade represents a 17.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by company insiders.

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.